Biotherapeutics News and Research

RSS

Oxygen Biotherapeutics to commence Phase II-b trial of Oxycyte in treating traumatic brain injury

Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has received approval from Israel's Ministry of Health to begin a Phase II-b, dose escalation, clinical trial in that country for use of Oxycyte(R) in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

23 Sep 2009

Preclinical data on Protalix Biotherapeutics' antiTNF released

Protalix Biotherapeutics, Inc., reported today preclinical data on pr-antiTNF, a biosimilar version of etanercept (Enbrel). Produced using the Company’s proprietary ProCellEx technology, pr-antiTNF is a plant cell expressed recombinant fusion protein made from the soluble form of the human TNF receptor (TNFR), fused to the Fc component of a human antibody IgG1 domain. Pr-antiTNF has an identical amino acid sequence to Enbrel.

23 Sep 2009

NASDAQ issues noncompliance letter to GTC Biotherapeutics

GTC Biotherapeutics, Inc.’s ("GTC", NASDAQ: GTCB) received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market (the “Staff Determination”) on September 17, 2009, indicating that unless GTC requests a hearing before the NASDAQ Listing Qualifications Panel (the “Panel”), the Company’s securities would be subject to delisting from The NASDAQ Capital Market due to non-compliance with the $35 million market value of listed securities requirement as set forth in Listing Rule 5550(b)(2).

19 Sep 2009

Juvaris BioTherapeutics completes first close on Series B equity financing

Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, announced that it has completed the first close on its Series B equity financing of up to $25 million led by SV Life Sciences (SVLS) along with existing investor, Kleiner Perkins Caufield & Byers (KPCB).

18 Sep 2009

GENova Biotherapeutics and Korean university sign strategic partnership agreement

GENova Biotherapeutics Inc. ("GENova") today announced that it has signed a LOI for a strategic partnership agreement with the Hospital Medical Information Department of Suncheon Cheongam University in Seoul, South Korea to gain access to its ground-breaking cancer stem cell research information.

18 Sep 2009

GENova and PacificWave sign engagement agreement

GENova Biotherapeutics Inc. ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced it has signed an engagement agreement with PacificWave Partners Limited ("PacWave") for raising a minimum of USD5m to the company as well as actively look for potential buy-out and/or acquisition targets.

17 Sep 2009

CI Index of ten leading cancer immunotherapy stocks increase by 58% in two months

The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 58% in its first two months of reporting. CI Index gain was paced by the 233% share price improvement of ImmunoCellular Theraputics, Inc. (IMUC.OB) under the leadership of CEO Manish Singh, Ph. D.

17 Sep 2009

GENova Biotherapeutics signs collaboration deal with Beckpharma

17 Sep 2009

GENova to sign extensive collaboration agreement with Beckpharma

GENova Biotherapeutics Inc. ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced it is in final negotiations with Beckpharma Ltd. ("Beckpharma") -a pharmaceutical development company also involved in cancer treatments for an extensive collaboration agreement.

17 Sep 2009

GENova in advanced negotiations to acquire patents from TheraGlass

GENova Biotherapeutics Inc. ("GENova") is pleased to announce that it is in advanced negotiations to acquire a number of patents from TheraGlass Ltd., a company that produces a ground-breaking regenerative bioactive material with exciting potential applications.

16 Sep 2009

GENova allies with academic institutions specializing in stem cell research

GENova Biotherapeutics Inc. ("GENova") today announced that it is forming strategic alliances with academic research institutions specializing in ground-breaking stem cell research.

16 Sep 2009

GENova Biotherapeutics signs LOI with Prime BioResearch

GENova Biotherapeutics Inc. ("GENova") today announced it has signed an LOI with Prime BioResearch, Ltd. ("Prime BioResearch"), another drug acquisition company in the areas of drug development and distribution a business case that will save GENova millions every year in drug development and at the same time more than double GENova's distribution network enabling GENova to potentially exceed its own expectations of reaching 100m+ in revenue in year.

16 Sep 2009

GENova Biotherapeutics and Prime BioResearch sign collaboration agreement

GENova Biotherapeutics Inc. ("GENova") today announced that it has signed a collaboration agreement with Prime BioResearch, Ltd. ("Prime BioResearch") the agreement is focused on how personalized medicine can be applied to cure cancer.

16 Sep 2009

Talecris launches initial public offering of shares

Talecris Biotherapeutics Holdings Corp. (“Talecris”) today announced the launch of its initial public offering of 44,736,842 shares of its common stock, par value $0.01 per share.

15 Sep 2009

Genova gains access to Big Pharma's distribution channels

GENova Biotherapeutics Inc. ("GENova"), a cancer drug acquisition and development company, is pleased to announce it has gained access to distribution channels for its promising drug targets through a recently-signed deal with Bridge BioResearch Plc. ("Bridge BioResearch").

15 Sep 2009

GENova Biotherapeutics and Bridge Bioresearch sign collaboration agreement

GENova Biotherapeutics Inc. ("GENova") today announced it has signed a collaboration agreement with Bridge Bioresearch Plc. ("Bridge Bioresearch"), an international drug development and discovery company that focuses on metabolic disorders.

15 Sep 2009

Protalix Biotherapeutics reports completion of its Phase III trial of prGCD

Protalix Biotherapeutics, Inc. (NYSE-Amex: PLX), announced the completion of its pivotal Phase III trial for prGCD, the Company’s proprietary plant-cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease. The trial enrolled a total of 31 patients across Europe, North America, South America, Israel and South Africa. No serious adverse events were reported in this trial.

14 Sep 2009

GENova to file for Prostaganin patents in the US and in Europe

GENova Biotherapeutics Inc. ("GENova") today announced that it is preparing for patent application filings in both the US (at the FDA (U.S. Food and Drug Administration (www.fda.gov) for a 510(k) submission) and in Europe through EMEA (European Medicines Agency) subsequent to expected efficacious and non-toxic pre-clinical results for Prostaganin.

14 Sep 2009

New stem cell technology could destroy breast cancer cells

GENova Biotherapeutics, Inc., ("GENova"), released important information about its innovative method for destroying breast cancer cells, using stem cell technology.

11 Sep 2009

GENova Biotherapeutics to obtain three new drug target patents

GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening diseases, is pleased to announce that it is in the process of acquiring three promising new drug target patents that could generate over a billion dollar in royalty fees in the mid to long term.

11 Sep 2009